Zymedyne Therapeutics

Zymedyne Therapeutics is a Canadian startup that is revolutionizing pain management with its slogan "Eliminating Opioids Painlessly." The company was founded in 2020 and focuses on developing safer and more effective treatments for chronic, neuropathic pain by targeting human Cav3.2 “T-type” calcium channels, which play a crucial role in pain signaling. Zymedyne's technology aims to provide pain relief without the detrimental side effects associated with opioid-based medications, such as weight gain, respiratory depression, and addiction. The company recently received a Seed Round investment on February 2, 2021 from UCeed. This investment underscores the growing interest and support for Zymedyne's innovative approach to pain management in the healthcare industry.